GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » Other Operating Expense

Shandong Wohua Pharmaceutical Co (SZSE:002107) Other Operating Expense : ¥68.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co Other Operating Expense?

Shandong Wohua Pharmaceutical Co's Other Operating Expense for the three months ended in Mar. 2024 was ¥1.5 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 was ¥68.9 Mil.

Shandong Wohua Pharmaceutical Co's quarterly Other Operating Expense increased from Sep. 2023 (¥-25.1 Mil) to Dec. 2023 (¥61.2 Mil) but then declined from Dec. 2023 (¥61.2 Mil) to Mar. 2024 (¥1.5 Mil).

Shandong Wohua Pharmaceutical Co's annual Other Operating Expense increased from Dec. 2021 (¥41.9 Mil) to Dec. 2022 (¥63.0 Mil) and increased from Dec. 2022 (¥63.0 Mil) to Dec. 2023 (¥70.1 Mil).


Shandong Wohua Pharmaceutical Co Other Operating Expense Historical Data

The historical data trend for Shandong Wohua Pharmaceutical Co's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Wohua Pharmaceutical Co Other Operating Expense Chart

Shandong Wohua Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.60 36.91 41.93 62.98 70.14

Shandong Wohua Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.75 31.34 -25.12 61.16 1.52

Shandong Wohua Pharmaceutical Co Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥68.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Wohua Pharmaceutical Co Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Shandong Wohua Pharmaceutical Co's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Traded in Other Exchanges
N/A
Address
Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011
Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.
Executives
Zhao Jun Director
Liu Wen Yi Supervisors
Zhang Fa Zhong Supervisors
Zhang Ge Director
Ma Xing Chen Supervisors
Tian Kai Ji Directors, executives
Kong Xian Jun Supervisors

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines